Time New York: Fri 22 Jun 01:53 am  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

BOK Financial Benefits From Loan Growth, High Costs a Drag

Zacks

On Jan 5, we issued an updated research report on BOK Financial Corporation BOKF). The company exhibits strength in several areas, including loans and deposits, and credit quality. However, it continues to face challenges from increasing expense base.

Shares of the company have gained 11.3% in a year’s time, against the 1.2% decline of the industry it belongs to.

Moreover, the Zacks Consensus Estimate for 2017 earnings has been revised slightly upward over the last 60 days. It currently carries a Zacks Rank #3 (Hold).



BOK Financial’s consistent improvement in loan and deposit balances highlights its organic growth. For full-year 2017, the company expects mid-single digit loan growth. Apart from rising loan balances, the company’s focus on expansion through strategic acquisitions should bolster its growth prospects.


BOK Financial’s nonperforming assets, charge offs and allowance for credit losses have been declining consistently over the past few years. It did not have provisions in the prior few years. Notably, management expects credit provisions of $15-$20 million for 2017.

However, the company faces operational risks from escalating costs. Operating expenses saw a CAGR of 4.9% over the last six years (2011-2016). This trend continued in first nine months of 2017 as well. Such consistent rise in expenses despite its focus on expense management is likely to deter bottom-line growth.

Stocks to Consider

Texas Capital Bancshares TCBI Zacks Consensus Estimate for earnings for 2017 was revised slightly upward, in the last 60 days. Also, its share price has increased 20.4% in the past 12 months. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rankstocks here.

Cullen/Frost Bankers CFR currently carries a Zacks Rank #2 (Buy). The stock’s 2017 earnings estimates were revised slightly upward, in the last 60 days. Further, the company’s shares have gained 30.2% in a year’s time.

Prosperity Bancshares PB Zacks Consensus Estimate for earnings for 2017 has remained stable, over the last 60 days. In the past year, its shares have gained 11.9%. Also, it carries a Zacks Rank of 2.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.